Synergy Pharma Completes Enrollment For Plecanatide Phase 2b Trial - Quick Facts

(RTTNews) - Synergy Pharmaceuticals Inc. (SGYP), Tuesday said it closed patient enrollment in its plecanatide phase 2b clinical trial in irritable bowel syndrome with constipation or IBS-C. Plecanatide is the company's lead guanylate cyclase-C agonist in development to treat patients with chronic idiopathic constipation and irritable bowel syndrome with constipation.

The 12-week trial is being conducted at about 70 sites in the U.S. and includes four doses of plecanatide, 0.3mg, 1.0mg, 3.0mg, 9.0mg, plus a placebo arm. The primary endpoint is change from baseline in the mean number of complete spontaneous bowel movement over the treatment period. The first patient was dosed on December 27, 2012 and Synergy expects to announce topline data in the beginning of fiscal 2014 second-quarter.